12:00 AM
 | 
Jun 11, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Quizartinib: Phase IIb started

The partners began an open-label, international Phase IIb trial to evaluate 2 doses of oral quizartinib in 28-day cycles in about 64 patients. In 2009, Ambit partnered with Astellas to develop and commercialize FLT3 inhibitors, including quizartinib, to treat AML...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >